Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | IP6K1 | Q92551 | 10/20 | 0.53 |
| ▸ | IP6K3 | Q96PC2 | 10/20 | 0.53 |
| ▸ | IP6K2 | Q9UHH9 | 10/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514440 | 0.89 | ALDH1A1 (0.62) | KMT2AMEN1ALDH1A1HPGDPOLB | |
| SCHEMBL3549996 | 0.88 | IP6K1 (0.62) | KMT2AMEN1NPC1ALDH1A1HPGD | |
| SCHEMBL5656312 | 0.85 | IP6K1 (0.55) | KMT2AMEN1ALDH1A1HPGDIP6K1 | |
| SCHEMBL3559449 | 0.85 | ALDH1A1 (0.58) | KMT2AMEN1ALDH1A1HPGDIP6K1 | |
| SCHEMBL5656276 | 0.80 | IP6K1 (0.51) | KMT2AMEN1NPC1ALDH1A1HPGD | |
| SCHEMBL5545666 | 0.80 | DOT1L (0.54) | KMT2AMEN1ALDH1A1HPGDIP6K1 | |
| SCHEMBL25991593 | 0.79 | IP6K1 (0.81) | KMT2AMEN1NPC1ALDH1A1HPGD | |
| SCHEMBL5022746 | 0.78 | IP6K1 (0.52) | KMT2AMEN1ALDH1A1HPGDIP6K1 | |
| SCHEMBL3557898 | 0.78 | HPGD (0.46) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL14434145 | 0.76 | IP6K1 (0.78) | KMT2AMEN1NPC1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655654-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7511138-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20080027086-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | ANGIBAUD PATRICK R | 2008-01-31 | — | — | US | disclosed |
| EP-1497295-B1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2006-08-16 | — | — | EP | disclosed |
| US-20050148609-A1 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles of triazoles | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | disclosed |
| EP-1497295-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087101-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148609-A1 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles of triazoles | FNTA, FNTB, HCCS | KMT2A 2748/4885MEN1 1369/4885NPC1 38/4885 |
| US-20080027086-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | FNTA, FNTB, CYP7A1 | KMT2A 2783/4885MEN1 1298/4885NPC1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.